Determination That CORDARONE (Amiodarone Hydrochloride) Tablets, 200 milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness, 38910-38911 [2017-17302]
Download as PDF
asabaliauskas on DSKBBXCHB2PROD with NOTICES
38910
Federal Register / Vol. 82, No. 157 / Wednesday, August 16, 2017 / Notices
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Stephanie L. Begansky, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–9001, Fax: 301–847–8533, email:
AADPAC@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
VerDate Sep<11>2014
18:33 Aug 15, 2017
Jkt 241001
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
SUPPLEMENTARY INFORMATION: Agenda:
The committees will discuss
supplemental new drug application
(sNDA) 021306, for BUTRANS
(buprenorphine) transdermal system
submitted by Purdue Pharma L.P.,
evaluating BUTRANS in pediatric
patients ages 7 through 16 years for
management of pain severe enough to
require daily, around-the-clock, longterm opioid treatment and for which
alternative treatment options are
inadequate. The committees will be
asked to discuss the findings of the
clinical study of BUTRANS conducted
in pediatric patients, and whether they
support additional labeling.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committees. All electronic
and written submissions submitted to
the docket (see ADDRESSES) on or before
August 30, 2017, will be provided to the
committees. Oral presentations from the
public will be scheduled between
approximately 10:15 a.m. and 11:15 a.m.
Those individuals interested in making
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before August 22, 2017. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by August 23, 2017.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require special accommodations
due to a disability, please contact
Stephanie L. Begansky at least 7 days in
advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: August 11, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–17303 Filed 8–15–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–P–0495]
Determination That CORDARONE
(Amiodarone Hydrochloride) Tablets,
200 milligrams, Were Not Withdrawn
From Sale for Reasons of Safety or
Effectiveness
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) has
determined that CORDARONE
(amiodarone hydrochloride) tablets, 200
milligrams (mg), were not withdrawn
from sale for reasons of safety or
effectiveness. This determination means
that FDA will not begin procedures to
withdraw approval of abbreviated new
drug applications (ANDAs) that refer to
this drug product, and it will allow FDA
to continue to approve ANDAs that refer
to the product as long as they meet
relevant legal and regulatory
requirements.
FOR FURTHER INFORMATION CONTACT:
Jennifer Forde, Center for Drug
SUMMARY:
E:\FR\FM\16AUN1.SGM
16AUN1
Federal Register / Vol. 82, No. 157 / Wednesday, August 16, 2017 / Notices
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6213,
Silver Spring, MD 20993–0002, 301–
348–3035.
In 1984,
Congress enacted the Drug Price
Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98–417)
(the 1984 amendments), which
authorized the approval of duplicate
versions of drug products under an
ANDA procedure. ANDA applicants
must, with certain exceptions, show that
the drug for which they are seeking
approval contains the same active
ingredient in the same strength and
dosage form as the ‘‘listed drug,’’ which
is a version of the drug that was
previously approved. ANDA applicants
do not have to repeat the extensive
clinical testing otherwise necessary to
gain approval of a new drug application
(NDA).
The 1984 amendments include what
is now section 505(j)(7) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
355(j)(7)), which requires FDA to
publish a list of all approved drugs.
FDA publishes this list as part of the
‘‘Approved Drug Products with
Therapeutic Equivalence Evaluations,’’
which is known generally as the
‘‘Orange Book.’’ Under FDA regulations,
drugs are removed from the list if the
Agency withdraws or suspends
approval of the drug’s NDA or ANDA
for reasons of safety or effectiveness or
if FDA determines that the listed drug
was withdrawn from sale for reasons of
safety or effectiveness (21 CFR 314.162).
A person may petition the Agency to
determine, or the Agency may
determine on its own initiative, whether
a listed drug was withdrawn from sale
for reasons of safety or effectiveness.
This determination may be made at any
time after the drug has been withdrawn
from sale, but must be made prior to
approving an ANDA that refers to the
listed drug (§ 314.161 (21 CFR 314.161)).
FDA may not approve an ANDA that
does not refer to a listed drug.
CORDARONE (amiodarone
hydrochloride) tablets, 200 mg, are the
subject of NDA 018972, held by Wyeth
Pharmaceuticals, Inc. (a subsidiary of
Pfizer, Inc.), and initially approved on
December 24, 1985. CORDARONE is
indicated for the treatment of the
following documented, life-threatening
recurrent ventricular arrhythmias when
these have not responded to
documented adequate doses of other
available antiarrhythmics or when
alternative agents could not be tolerated:
(1) Recurrent ventricular fibrillation and
asabaliauskas on DSKBBXCHB2PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
18:33 Aug 15, 2017
Jkt 241001
(2) recurrent hemodynamically unstable
ventricular tachycardia.
In correspondence dated February 7,
2017, Pfizer, Inc. notified FDA that
CORDARONE (amiodarone
hydrochloride) tablets, 200 mg, were
being discontinued, and FDA moved the
drug product to the ‘‘Discontinued Drug
Product List’’ section of the Orange
Book.
Lachman Consultant Services, Inc.
submitted a citizen petition dated
January 25, 2017 (Docket No. FDA–
2017–P–0495), under 21 CFR 10.30,
requesting that the Agency determine
whether CORDARONE (amiodarone
hydrochloride) tablets, 200 mg, were
withdrawn from sale for reasons of
safety or effectiveness.
After considering the citizen petition
and reviewing Agency records and
based on the information we have at this
time, FDA has determined under
§ 314.161 that CORDARONE
(amiodarone hydrochloride) tablets, 200
mg, were not withdrawn for reasons of
safety or effectiveness. The petitioner
has identified no data or other
information suggesting that
CORDARONE (amiodarone
hydrochloride) tablets, 200 mg, were
withdrawn for reasons of safety or
effectiveness. We have carefully
reviewed our files for records
concerning the withdrawal of
CORDARONE (amiodarone
hydrochloride) tablets, 200 mg, from
sale. We have also independently
evaluated relevant literature and data
for possible postmarketing adverse
events. We have reviewed the available
evidence and determined that this drug
product was not withdrawn from sale
for reasons of safety or effectiveness.
Accordingly, the Agency will
continue to list CORDARONE
(amiodarone hydrochloride) tablets, 200
mg, in the ‘‘Discontinued Drug Product
List’’ section of the Orange Book. The
‘‘Discontinued Drug Product List’’
delineates, among other items, drug
products that have been discontinued
from marketing for reasons other than
safety or effectiveness. FDA will not
begin procedures to withdraw approval
of approved ANDAs that refer to this
drug product. Additional ANDAs for
this drug product may also be approved
by the Agency as long as they meet all
other legal and regulatory requirements
for the approval of ANDAs. If FDA
determines that labeling for this drug
product should be revised to meet
current standards, the Agency will
advise ANDA applicants to submit such
labeling.
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
38911
Dated: August 11, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–17302 Filed 8–15–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–3966]
Upsher-Smith Laboratories, Inc.;
Withdrawal of Approval of an
Abbreviated New Drug Application for
ZALEPLON
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or the Agency) is
withdrawing approval of an abbreviated
new drug application (ANDA) for
ZALEPLON Capsules, 5 milligrams (mg)
and 10 mg, held by Upsher-Smith
Laboratories, Inc. (Upsher-Smith), 6701
Evenstad Dr., Maple Grove, MN 55369.
Upsher-Smith has voluntarily requested
that approval of this application be
withdrawn, and has waived its
opportunity for a hearing.
DATES: Effective August 16, 2017.
FOR FURTHER INFORMATION CONTACT:
Stefanie Kraus, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6215,
Silver Spring, MD 20993–0002, 301–
796–9585.
SUPPLEMENTARY INFORMATION: On June 6,
2008, FDA approved ANDA 078706 for
ZALEPLON Capsules, 5 mg and 10 mg,
submitted by Upsher-Smith. According
to annual reports Upsher-Smith filed
with the Agency, Upsher-Smith stopped
distributing these products by April 6,
2010. In a letter dated August 9, 2011,
FDA informed Upsher-Smith that it had
concerns about the validity of
bioequivalence data submitted with
ANDA 078706 from studies conducted
by a certain contract research
organization, establishing
bioequivalence of Upsher-Smith’s
product to the reference listed drug,
SONATA (ZALEPLON) Capsules, 5 mg
and 10 mg. In that letter, FDA directed
Upsher-Smith to supplement its ANDA
with either: (1) New bioequivalence
studies or (2) re-assays of the samples
from the original bioequivalence
studies. Upsher-Smith did not respond
to this letter. FDA then sent another
letter to Upsher-Smith on August 19,
SUMMARY:
E:\FR\FM\16AUN1.SGM
16AUN1
Agencies
[Federal Register Volume 82, Number 157 (Wednesday, August 16, 2017)]
[Notices]
[Pages 38910-38911]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-17302]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-P-0495]
Determination That CORDARONE (Amiodarone Hydrochloride) Tablets,
200 milligrams, Were Not Withdrawn From Sale for Reasons of Safety or
Effectiveness
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) has
determined that CORDARONE (amiodarone hydrochloride) tablets, 200
milligrams (mg), were not withdrawn from sale for reasons of safety or
effectiveness. This determination means that FDA will not begin
procedures to withdraw approval of abbreviated new drug applications
(ANDAs) that refer to this drug product, and it will allow FDA to
continue to approve ANDAs that refer to the product as long as they
meet relevant legal and regulatory requirements.
FOR FURTHER INFORMATION CONTACT: Jennifer Forde, Center for Drug
[[Page 38911]]
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6213, Silver Spring, MD 20993-0002, 301-
348-3035.
SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price
Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417)
(the 1984 amendments), which authorized the approval of duplicate
versions of drug products under an ANDA procedure. ANDA applicants
must, with certain exceptions, show that the drug for which they are
seeking approval contains the same active ingredient in the same
strength and dosage form as the ``listed drug,'' which is a version of
the drug that was previously approved. ANDA applicants do not have to
repeat the extensive clinical testing otherwise necessary to gain
approval of a new drug application (NDA).
The 1984 amendments include what is now section 505(j)(7) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which
requires FDA to publish a list of all approved drugs. FDA publishes
this list as part of the ``Approved Drug Products with Therapeutic
Equivalence Evaluations,'' which is known generally as the ``Orange
Book.'' Under FDA regulations, drugs are removed from the list if the
Agency withdraws or suspends approval of the drug's NDA or ANDA for
reasons of safety or effectiveness or if FDA determines that the listed
drug was withdrawn from sale for reasons of safety or effectiveness (21
CFR 314.162).
A person may petition the Agency to determine, or the Agency may
determine on its own initiative, whether a listed drug was withdrawn
from sale for reasons of safety or effectiveness. This determination
may be made at any time after the drug has been withdrawn from sale,
but must be made prior to approving an ANDA that refers to the listed
drug (Sec. 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that
does not refer to a listed drug.
CORDARONE (amiodarone hydrochloride) tablets, 200 mg, are the
subject of NDA 018972, held by Wyeth Pharmaceuticals, Inc. (a
subsidiary of Pfizer, Inc.), and initially approved on December 24,
1985. CORDARONE is indicated for the treatment of the following
documented, life-threatening recurrent ventricular arrhythmias when
these have not responded to documented adequate doses of other
available antiarrhythmics or when alternative agents could not be
tolerated: (1) Recurrent ventricular fibrillation and (2) recurrent
hemodynamically unstable ventricular tachycardia.
In correspondence dated February 7, 2017, Pfizer, Inc. notified FDA
that CORDARONE (amiodarone hydrochloride) tablets, 200 mg, were being
discontinued, and FDA moved the drug product to the ``Discontinued Drug
Product List'' section of the Orange Book.
Lachman Consultant Services, Inc. submitted a citizen petition
dated January 25, 2017 (Docket No. FDA-2017-P-0495), under 21 CFR
10.30, requesting that the Agency determine whether CORDARONE
(amiodarone hydrochloride) tablets, 200 mg, were withdrawn from sale
for reasons of safety or effectiveness.
After considering the citizen petition and reviewing Agency records
and based on the information we have at this time, FDA has determined
under Sec. 314.161 that CORDARONE (amiodarone hydrochloride) tablets,
200 mg, were not withdrawn for reasons of safety or effectiveness. The
petitioner has identified no data or other information suggesting that
CORDARONE (amiodarone hydrochloride) tablets, 200 mg, were withdrawn
for reasons of safety or effectiveness. We have carefully reviewed our
files for records concerning the withdrawal of CORDARONE (amiodarone
hydrochloride) tablets, 200 mg, from sale. We have also independently
evaluated relevant literature and data for possible postmarketing
adverse events. We have reviewed the available evidence and determined
that this drug product was not withdrawn from sale for reasons of
safety or effectiveness.
Accordingly, the Agency will continue to list CORDARONE (amiodarone
hydrochloride) tablets, 200 mg, in the ``Discontinued Drug Product
List'' section of the Orange Book. The ``Discontinued Drug Product
List'' delineates, among other items, drug products that have been
discontinued from marketing for reasons other than safety or
effectiveness. FDA will not begin procedures to withdraw approval of
approved ANDAs that refer to this drug product. Additional ANDAs for
this drug product may also be approved by the Agency as long as they
meet all other legal and regulatory requirements for the approval of
ANDAs. If FDA determines that labeling for this drug product should be
revised to meet current standards, the Agency will advise ANDA
applicants to submit such labeling.
Dated: August 11, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-17302 Filed 8-15-17; 8:45 am]
BILLING CODE 4164-01-P